Divi's Laboratories Limited disclosed on April 06, 2026, that its promoter group has not encumbered any shares during the financial year ended March 31, 2026. The declaration, submitted to the National Stock Exchange of India and BSE Limited, confirms that no shares were pledged directly or indirectly by the promoters or Persons Acting in Concert (PAC). This disclosure is significant for shareholders as it indicates the absence of leverage risk against the promoter holding, which accounts for over half of the company's total equity.

The filing was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Dr. Murali K. Divi, Promoter and Managing Director, signed the disclosure on behalf of the promoter group. The statement covers the promoter group's entire shareholding, ensuring transparency regarding the ownership status of the key stakeholders in the company.

The promoter group, including Dr. Murali K. Divi and other PAC members, collectively holds 13,75,67,000 equity shares. This represents 51.82% of the company's total share capital and total diluted share capital. The largest individual holdings within the group are attributed to Dr. Kiran Satchandra Divi and Nilima Prasad Divi, each holding 20.34% of the total share capital.

The following table details the shareholding pattern of the promoter group as disclosed in the filing:

The confirmation of no encumbrance provides stability to the shareholding structure of Divis Laboratories . The document was signed in Hyderabad on April 06, 2026, and a copy was forwarded to the Audit Committee of the company for its records.

Divi's Laboratories Limited has recommended a dividend of ₹30 per fully paid-up equity share of face value ₹2 each for the financial year ended March 31, 2026. The declaration, amounting to 1,500%, is subject to approval by shareholders at the 36th Annual General Meeting scheduled for August 10, 2026. The record date to determine eligibility is July 24, 2026, with payment expected on or after August 14, 2026.

The company has outlined the tax deduction at source (TDS) implications under the Income-tax Act, 2025. For resident shareholders with a valid Permanent Account Number (PAN), TDS will be deducted at 10%. If PAN is invalid, inoperative, or not registered, the deduction rate increases to 20%. Resident individuals are exempt from TDS if the total dividend does not exceed ₹10,000 or if Form 121 is submitted.

Resident non-individual entities such as insurance companies, mutual funds, and Alternative Investment Funds (AIF) can claim exemption by submitting specific self-declarations and registration documents. Non-resident shareholders face a withholding tax rate of 20%, plus applicable surcharge and cess, unless they provide a certificate for lower or nil withholding or opt for benefits under the Double Tax Avoidance Agreement (DTAA).

To avail lower withholding rates under Section 395, shareholders must ensure the certificate is issued against the company's TAN: HYDD00401C. Certificates issued against any other TAN will not be accepted. Non-resident shareholders seeking DTAA benefits must provide a Tax Residency Certificate, e-filed Form 41, and a self-declaration meeting treaty eligibility requirements by the cut-off date.

Shareholders must submit all relevant tax documents, including Form 121 and residency declarations, on or before July 24, 2026. Documents can be uploaded via the KFintech portal or emailed to the designated addresses. Submissions received after this date may not be considered, potentially resulting in a higher TDS deduction. The company clarified that it is not obligated to apply beneficial DTAA rates if documentation is incomplete or unsatisfactory.

The company also advised shareholders to update bank details, particularly those holding shares in physical form, to ensure electronic dividend payments as per SEBI regulations.